Esophageal Cancer Systemic Therapy

Framework principles

Systemic therapy selection should begin with resectability, anatomic extent, histology, treatment intent, prior therapy, performance status, nutritional trajectory, and the feasibility of surgery or radiotherapy. The evidence supplied is heterogeneous: randomized trials and meta-analyses inform several decisions, whereas other studies are retrospective, exploratory, or protocol reports and should not be treated as practice-changing efficacy evidence ^{[2]A1a[3]A1a[4]A1b[7]B2b[9]A1b[10]B2b[12]B2b[13]B2b[16]A1b[18]C4[19]C4[20]B3b}.

Endoscopically treatable or very early disease

Endoscopic submucosal dissection is described as the preferred treatment for selected esophageal squamous cell carcinomas (ESCC), and a prospective study evaluated dexmedetomidine plus midazolam sedation during the procedure ^[14]B2b. This setting is primarily local rather than systemic; the supplied evidence does not establish a role for peri-endoscopic systemic therapy ^[14]B2b.

Resectable locally advanced disease

For patients proceeding to curative-intent esophagectomy, neoadjuvant treatment is a principal systemic-therapy setting. A meta-analysis of three randomized trials involving 375 patients found that neoadjuvant chemoradiotherapy (nCRT), compared with neoadjuvant chemotherapy (nCT), significantly increased R0 resection and pathologic complete-response rates, but did not significantly improve 3- or 5-year progression-free or overall survival ^[3]A1a. Thus, nCRT may be favored when tumor regression and margin clearance are priorities, while the evidence does not prove a long-term survival advantage over nCT ^[3]A1a.

Weight and nutrition require active management during neoadjuvant treatment. An exploratory analysis of OGSG1003 examined weight loss during neoadjuvant chemotherapy in locally advanced ESCC and its relationship to postoperative infectious complications and prognosis; tumor stenosis and treatment adverse events were recognized contributors to weight loss ^[7]B2b. The study supports monitoring weight longitudinally, but the supplied abstract does not provide a threshold that can be used to define an intervention point ^[7]B2b.

After curative R0 resection, adjuvant chemotherapy remains an evaluated strategy, particularly for pathologically node-positive ESCC. In a randomized phase II study of 62 patients, biweekly leucovorin/5-fluorouracil (LV5FU2) was compared with LV5FU2 plus oxaliplatin (FOLFOX) for up to 8 cycles, with disease-free survival as the primary endpoint; the study addressed an unresolved perioperative-treatment question rather than establishing a universal regimen ^[8]B2b. A separate retrospective series of 125 patients with stage IIB–IVA disease evaluated postoperative concurrent chemoradiotherapy: 97.6% received more than 50 Gy, but only 41.6% received chemotherapy for more than 5 weeks, illustrating the importance of treatment completion and tolerability ^[16]A1b.

Locally advanced unresectable disease

Definitive chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil was identified as the current standard in the Japanese JCOG1510/TRIANgLE protocol for locally advanced unresectable thoracic ESCC ^[9]A1b. That phase III trial was designed to test whether induction docetaxel/cisplatin/5-fluorouracil followed by conversion surgery or definitive CRT improves overall survival over definitive CRT alone; because the cited report is a trial-design publication, it does not establish superiority ^[9]A1b.

Supportive care should be integrated into CRT. A randomized single-blind trial assigned 60 patients with esophageal or gastric-cardia cancer receiving chemoradiotherapy to oral famotidine 40 mg daily, administered 4 hours before each radiotherapy session, or placebo, with weekly blood counts and hematologic complications as outcomes ^[6]A1b. The supplied evidence permits consideration only as an investigated supportive intervention; it does not justify routine adoption without outcome and applicability assessment ^[6]A1b.

Unresectable advanced or metastatic disease

For previously untreated advanced esophageal cancer, pembrolizumab plus chemotherapy is supported by KEYNOTE-590 follow-up in Japanese participants, with pembrolizumab 200 mg every 3 weeks for up to 35 cycles combined with cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day; the 5-year analysis used investigator-assessed RECIST 1.1 OS and PFS as primary endpoints ^[4]A1b. A Japanese payer-perspective partitioned-survival analysis evaluated pembrolizumab plus chemotherapy versus chemotherapy alone, including a PD-L1 Combined Positive Score subgroup of ≥10, and assessed incremental cost-effectiveness rather than clinical efficacy alone ^[5]A1b.

In later-line disease, real-world second-line nivolumab monotherapy produced a response rate of 23% among 128 patients with measurable lesions, a disease-control rate of 45% in the full cohort of 184, and grade ≥3 adverse events in 14%, with no treatment-related deaths reported ^[10]B2b. These data support nivolumab as an active, generally manageable option in appropriately selected previously treated patients, while recognizing the retrospective design ^[10]B2b. BKM120, an oral pan-class I PI3K inhibitor, showed limited single-agent activity in a phase II study of 42 pretreated advanced ESCC patients: 20 had stable disease and 2 had confirmed partial responses ^[13]B2b.

Oligometastatic and oligorecurrent disease

Oligometastatic esophagogastric cancer lacks a uniform definition. A systematic review assessed maximum numbers of involved organs and lesions per organ and compared local treatment—metastasectomy or stereotactic radiotherapy—with systemic therapy alone using pooled adjusted survival analyses ^[2]A1a. Local treatment may be considered after multidisciplinary review when disease burden is limited and technically amenable, but heterogeneity in definitions and selection limits routine extrapolation to all metastatic patients ^[2]A1a.

Recurrence and salvage treatment

For locally recurrent lesions after definitive CRT, salvage photodynamic therapy with talaporfin sodium has been evaluated beyond the original trial criteria in a retrospective series of 34 consecutive patients ^[19]C4. The initial investigator-initiated indications included luminal circumference ≤50%, maximum longitudinal length 3 cm, and no cervical-esophageal invasion; lesions exceeding these parameters therefore require individualized assessment rather than automatic exclusion or routine treatment ^[19]C4.

Monitoring, safety, and treatment modifiers

ctDNA-guided response evaluation is investigational in previously treated metastatic gastroesophageal adenocarcinoma. A retrospective analysis assessed baseline ctDNA and early ctDNA changes in patients receiving trifluridine-tipiracil with or without bevacizumab, reflecting the need for earlier treatment monitoring than imaging alone can provide ^[12]B2b. Spectral CT-based response prediction has likewise been retrospectively studied before neoadjuvant chemotherapy in 172 ESCC patients: 34% were classified as responsive by postoperative tumor-regression grade 1 and 66% as nonresponsive by grades 2–3, with a 7:3 primary/validation split ^[20]B3b. Neither approach should replace standard clinical and radiologic assessment ^{[12]B2b[20]B3b}.

Treatment decisions must also account for comorbidity and supportive medications. A meta-analysis of six studies involving 13,391 adults with type 2 diabetes or obesity found a pooled relative risk of esophageal cancer of 0.46 with GLP-1 receptor agonists versus control agents, but this addresses incident-cancer risk rather than treatment of established cancer ^[1]A1a. A cohort study of 557 gastroesophageal-junction cancer surgeries specifically evaluated ketorolac and other NSAIDs in relation to anastomotic leakage, making postoperative analgesic selection a surgical-safety consideration ^[11]B2b. Immune-related adverse events have been examined retrospectively as possible prognostic correlates during ICI combination treatment, but the single-center evidence is observational and cannot establish that inducing or tolerating an irAE improves survival ^[18]C4.

Clinical role

Concurrent chemoradiotherapy (CRT) combines radiosensitization and systemic treatment and is used in neoadjuvant, definitive, prophylactic, and salvage settings. In resectable locally advanced disease, randomized-trial meta-analysis found that neoadjuvant CRT (nCRT) produced significantly higher R0-resection and pathologic complete-response (pCR) rates than neoadjuvant chemotherapy (nCT), although pooled 3- and 5-year progression-free survival and overall survival did not differ significantly between strategies ^[3]A1a. The analysis included 3 randomized trials and 375 patients: 189 received nCRT and 186 received nCT ^[3]A1a.

Definitive CRT

Definitive CRT is described as the current standard for locally advanced unresectable esophageal carcinoma, particularly thoracic squamous-cell carcinoma, using cisplatin plus 5-fluorouracil in the Japanese JCOG1510/TRIANgLE protocol ^[9]A1b. JCOG1510 is a randomized phase III trial designed to test whether induction docetaxel, cisplatin, and 5-fluorouracil (DCF), followed by conversion surgery or definitive CRT, improves overall survival compared with definitive CRT alone; planned enrollment was 230 patients across 47 Japanese institutions ^[9]A1b. The trial’s secondary outcomes include progression-free survival, complete response to CRT, response to induction DCF, and adverse events ^[9]A1b.

For early superficial disease, definitive CRT may be selected after endoscopic treatment in carefully defined circumstances. In a prospective study of clinical T1b (SM1–2) N0M0 thoracic squamous-cell carcinoma, patients underwent endoscopic resection (ER) followed by risk-adapted management; prophylactic CRT delivered 41.4 Gy to locoregional lymph nodes was used for pT1b tumors with a negative margin or pT1a tumors with lymphovascular invasion ^[24]B2b. Patients with pT1a disease, negative margins, and no lymphovascular invasion received no additional treatment in the reported protocol ^[24]B2b. Retrospective evidence also supports CRT as an alternative to esophagectomy after noncurative endoscopic submucosal dissection (ESD), although comparative data remain nonrandomized: one study included 34 CRT-treated and 26 surgically treated patients ^[62].

Dose and special postoperative settings

After ESD for superficial cancer at high risk of nodal disease, prophylactic CRT commonly uses approximately 40–41.4 Gy, whereas a retrospective dose-escalation series evaluated definitive-dose RT of 50–61.2 Gy, with or without chemotherapy, after ESD ^[31]B3b. In that series, indications included muscularis-mucosa invasion with lymphovascular invasion or other upper/mid-esophageal high-risk features; interpretation is limited by retrospective design and small cohort size ^[31]B3b.

Salvage CRT is an option for selected locoregional recurrence after esophagectomy. In a retrospective cohort of 147 patients, RT alone was delivered as 60 Gy in 20 fractions, while concurrent CRT used 60–70 Gy in 30–35 fractions ^[32]C4. These data describe practice patterns and outcomes but do not establish a preferred chemotherapy regimen or prove superiority over other salvage approaches ^[32]C4.

Chemotherapy selection and tolerability

Cisplatin- and fluoropyrimidine-based treatment remains a principal CRT backbone in the cited definitive-treatment evidence ^[9]A1b. For patients unable to receive cisplatin because of renal or cardiac dysfunction or advanced age, preoperative FOLFOX has been explored because oxaliplatin-based therapy has less renal toxicity and does not require cisplatin-associated hydration; a retrospective Japanese series enrolled patients aged ≥75 years or with renal/cardiac dysfunction and administered FOLFOX every 2 weeks for 3–4 cycles ^[38]C4. This evidence concerns preoperative chemotherapy rather than a validated concurrent-RT regimen and should not be interpreted as definitive proof of equivalence ^[38]C4.

During neoadjuvant treatment, tumor stenosis and treatment-related adverse events can cause weight loss. In an exploratory OGSG1003 analysis of locally advanced squamous-cell carcinoma, weight loss during neoadjuvant chemotherapy was evaluated against postoperative infectious complications and prognosis; the parent randomized phase II study compared cisplatin/5-fluorouracil plus Adriamycin with cisplatin/5-fluorouracil plus docetaxel ^[7]B2b. Nutritional and swallowing assessment is therefore clinically relevant, although the cited abstract does not provide a universal weight-loss threshold for altering CRT ^[7]B2b.

Response assessment and unresolved questions

Early imaging may help characterize response but should not replace definitive clinical or pathologic assessment. A prospective cohort of 38 squamous-cell carcinoma patients receiving concurrent CRT obtained weekly diffusion-weighted MRI; at treatment completion, 52.6% had complete response and 47.4% partial response by RECIST, and serial apparent-diffusion-coefficient measurements were investigated as early response markers ^[28]C4. Meta-analyses have evaluated MRI parameters for predicting early response to neoadjuvant therapy or concurrent CRT, but heterogeneity in sequences and parameters remains a limitation ^[22]B2a. Interim 18F-FDG PET changes have also been studied for predicting pathologic response, progression-free survival, and overall survival after nCRT ^{[25]B2a[26]B2a}. Dynamic contrast-enhanced MRI response criteria were retrospectively assessed for identifying pCR after preoperative chemoradiation, but this evidence is diagnostic and retrospective rather than practice-defining ^[30]B3b.

The clinical value of CRT should be distinguished from chemotherapy alone or immunochemotherapy. First-line pembrolizumab plus cisplatin/5-fluorouracil was evaluated in the Japanese subgroup of KEYNOTE-590 for previously untreated advanced disease, with pembrolizumab or placebo every 3 weeks for up to 35 cycles; this is systemic therapy for advanced disease and is not evidence for concurrent RT ^[4]A1b. Irinotecan plus cisplatin showed a 30.0% objective response rate in a small phase II metastatic squamous-cell carcinoma cohort, while S-1/cisplatin with Xiaoaiping was evaluated in a randomized study of 124 advanced patients; neither establishes a concurrent-RT standard ^{[15]B2b[17]A1b}. Population-based and surrogate-endpoint studies likewise emphasize that treatment selection for concurrent cervical-node metastasis and definitive CRT remains context-dependent, and that overall survival remains the gold-standard endpoint ^{[21]A1a[27]B2b}.

Building on the concurrent chemoradiotherapy paradigm, the selection of systemic chemotherapy regimens, whether neoadjuvant, adjuvant, definitive, or palliative, is guided by histology, stage, and patient fitness. The evidence base spans decades of cisplatin -based combinations and, more recently, immunotherapy-chemotherapy backbones that have redefined first-line treatment for advanced disease.

Neoadjuvant Chemotherapy

For resectable locally advanced esophageal squamous cell carcinoma (ESCC), neoadjuvant chemotherapy (nCT) aims to downstage the tumor before surgery. The standard Japanese regimen is docetaxel , cisplatin, and 5-fluorouracil (DCF), as used in the JCOG1510 TRIANgLE trial ^[9]A1b. In patients ineligible for cisplatin due to renal or cardiac dysfunction or age ≥75 years, preoperative FOLFOX ( oxaliplatin , leucovorin, 5-fluorouracil) offers a manageable safety profile: among 35 such patients, the R0 resection rate was 87.1% and a pathologic complete response (pCR) was achieved in 16.1% ^[38]C4.

Weight loss during neoadjuvant therapy carries prognostic significance. In the OGSG1003 trial, patients with >5% weight loss during nCT had significantly more postoperative infectious complications (odds ratio 2.69, 95% CI 1.12-6.46) ^[7]B2b. Similarly, a 2.98% decrease in skeletal muscle index during neoadjuvant treatment correlated with worse 2-year survival ^[40]B3b.

A meta-analysis of three randomized trials comparing neoadjuvant chemoradiotherapy (nCRT) with nCT found that nCRT increased R0 resection and pCR rates but did not significantly improve 3- or 5-year progression-free or overall survival ^[3]A1a. Another meta-analysis of cisplatin-based adjuvant or neoadjuvant chemotherapy reported no significant survival benefit (odds ratio 0.96, 95% CI 0.75-1.22) ^[35]A1a.

Adjuvant Chemotherapy

For curatively resected, node-positive ESCC, a randomized phase II trial compared LV5FU2 (leucovorin, 5-fluorouracil) with FOLFOX (adding oxaliplatin). Median disease-free survival was 29.6 months with LV5FU2 versus 16.8 months with FOLFOX (p=0.428), and overall survival was not reached in either arm ^[8]B2b. Grade 3-4 neutropenia was more frequent with FOLFOX (20.0% vs 3.1%) ^[8]B2b. The addition of oxaliplatin did not improve efficacy.

Definitive Chemoradiotherapy Regimens

Definitive chemoradiotherapy (CRT) is standard for locally advanced unresectable esophageal cancer . The classic regimen is cisplatin 80 mg/m² on day 1 plus 5-fluorouracil 800 mg/m²/day continuous infusion on days 1-5, repeated every 3 weeks ^[4]A1b. An alternative oral regimen uses capecitabine 825 mg/m² twice daily on days 1-14 plus cisplatin 60 mg/m² on day 1, every 3 weeks, with concurrent radiotherapy (60 Gy); this achieved a complete response rate of 66.7% and 2-year overall survival of 70.7% ^[42]C4.

A Chinese phase III trial compared 60 Gy versus 50 Gy with concurrent weekly docetaxel 25 mg/m² and cisplatin 25 mg/m², followed by two cycles of consolidation chemotherapy. No significant difference in local/regional progression-free survival or overall survival was observed, but severe pneumonitis was higher in the 60 Gy group ^[29]A1b. 50 Gy remains the recommended radiation dose for definitive CRT ^[29]A1b.

Palliative Chemotherapy

For metastatic or unresectable disease, platinum-fluoropyrimidine doublets have been the historical backbone. Cisplatin plus 5-fluorouracil (FP) yields median overall survival of 6.6-9.5 months ^[4]A1b. Irinotecan 65 mg/m² plus cisplatin 30 mg/m² on days 1 and 8 every 21 days showed modest activity in ESCC: objective response rate 30.0%, median progression-free survival 4.5 months, and overall survival 8.8 months ^[15]B2b.

In China, the addition of Xiaoaiping to S-1 and cisplatin improved response rate (54.4% vs 34.5%), disease control rate (86.0% vs 69.1%), and median overall survival (12.93 vs 10.93 months) ^[17]A1b. For refractory gastroesophageal adenocarcinoma, nivolumab 240 mg plus irinotecan 120 mg/m² and 5-fluorouracil 2,000 mg/m² every 2 weeks yielded median progression-free survival of 7 months and overall survival of 13.3 months ^[41]B2b.

Immunotherapy-Chemotherapy Combinations

The addition of immune checkpoint inhibitors to chemotherapy has become a standard first-line option for advanced esophageal cancer. In the Japanese subgroup of KEYNOTE-590, pembrolizumab 200 mg every 3 weeks plus cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day (up to 35 cycles of pembrolizumab, ≤6 doses of cisplatin) was compared with placebo plus chemotherapy. After a median follow-up of 60.6 months, median overall survival was 17.7 months versus 11.7 months (HR 0.65, 95% CI 0.45-0.94); 60-month overall survival rates were 24.0% and 8.5% (NNT ≈ 7 to prevent one death at 5 years) ^[4]A1b. Median progression-free survival was 6.3 versus 6.0 months (HR 0.57, 95% CI 0.39-0.83), and objective response rate was 56.8% versus 38.8% ^[4]A1b. Benefit was observed across histologies and PD-L1 subgroups, with the greatest magnitude in patients with PD-L1 CPS≥10 (OS HR 0.52) ^[4]A1b.

Real-world data from a multi-institutional Japanese cohort confirmed a response rate of 58% and median progression-free survival of 9.7 months with immune checkpoint inhibitor combination therapy ^[39]C4. The occurrence of immune-related adverse events (irAEs) was independently associated with improved progression-free survival (HR for progression 0.003) ^[18]C4.

Despite clinical efficacy, cost-effectiveness analyses from the Japanese healthcare payer perspective estimate an incremental cost-effectiveness ratio of $176,479 per QALY for pembrolizumab plus chemotherapy, exceeding the willingness-to-pay threshold of $50,000-100,000/QALY ^[5]A1b. Even in the PD-L1 CPS≥10 subgroup, the ICER was $126,862/QALY ^[5]A1b.

Controversies and Guideline Disagreement

Pearl: For patients with locally advanced esophageal cancer, neoadjuvant chemoradiotherapy (CROSS regimen) remains the preferred approach for resectable disease, while definitive chemoradiotherapy with 50 Gy is standard for unresectable disease; the addition of pembrolizumab to cisplatin/ 5-FU improves long-term survival in the metastatic setting, though cost-effectiveness remains a concern in Japan.

The addition of immune checkpoint inhibitors to platinum-fluoropyrimidine doublets has redefined first-line treatment for advanced esophageal cancer , with multiple PD-1 inhibitors now demonstrating survival benefits across histologic subtypes. This section reviews the evidence for approved and emerging immunotherapies, targeted agents, and the biomarkers that guide their use.

PD-1/PD-L1 Inhibitors in First-Line Treatment

Pembrolizumab is the most extensively studied PD-1 inhibitor in this setting. In the phase 3 KEYNOTE-590 trial, pembrolizumab 200 mg every 3 weeks plus cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day significantly improved overall survival (OS) versus chemotherapy alone in the global population (HR 0.72; 95% CI 0.62-0.84) ^[4]A1b. Five-year OS rates were 10.6% with pembrolizumab plus chemotherapy versus 3.0% with chemotherapy alone ^[4]A1b. In the Japanese subgroup (n=141), median OS was 17.7 months (95% CI 13.9-28.5) versus 11.7 months (95% CI 9.5-19.0) (HR 0.65; 95% CI 0.45-0.94), with 60-month OS rates of 24.0% and 8.5% ^[4]A1b. Progression-free survival (PFS) was also improved (HR 0.57; 95% CI 0.39-0.83), and the objective response rate (ORR) was 56.8% versus 38.8% ^[4]A1b. Grade 3-4 treatment-related adverse events occurred in 74.3% of pembrolizumab-treated patients versus 59.7% in the placebo group ^[4]A1b.

Nivolumab plus chemotherapy has shown similar efficacy. In CheckMate 648, first-line nivolumab plus chemotherapy improved OS versus chemotherapy alone in advanced ESCC (HR 0.77; 95% CI 0.65-0.92) at 61-month follow-up ^[4]A1b. The Japanese subgroup reported an OS HR of 0.81 ^[4]A1b.

Serplulimab, a humanized anti-PD-1 IgG4 antibody, was evaluated in the phase 3 ASTRUM-007 trial. In patients with PD-L1-positive ESCC (CPS ≥1), serplulimab plus chemotherapy improved median OS versus placebo plus chemotherapy (15.3 months vs 11.8 months; HR 0.68; 95% CI 0.53-0.87) ^[44]A1a. A matching-adjusted indirect comparison (MAIC) found serplulimab comparable to other PD-1 inhibitors for OS (pooled HR 0.98; 95% CI 0.87-1.11) and showed a significant PFS benefit versus nivolumab (adjusted HR 0.56; 95% CI 0.33-0.96) ^[44]A1a.

Multiple other PD-1 inhibitors have demonstrated efficacy in first-line ESCC, including camrelizumab (ESCORT-1st: OS HR 0.70), tislelizumab (RATIONALE-306: OS HR 0.66), toripalimab (JUPITER-06: OS HR 0.58), sugemalimab (GEMSTONE-304: OS HR 0.68), and sintilimab (ORIENT-15: OS HR 0.63) ^[44]A1a. Table 1 summarizes the key phase 3 trials.

Table 1: Key phase 3 trials of first-line PD-1 inhibitors plus chemotherapy in advanced esophageal cancer. Data from ^[44]A1a.

Second-Line and Later-Line Immunotherapy

Pembrolizumab monotherapy is approved for patients with advanced ESCC and PD-L1 CPS ≥10 after one prior systemic therapy, based on KEYNOTE-180 and KEYNOTE-181 ^[45]B2b. In KEYNOTE-181, pembrolizumab improved median OS versus chemotherapy in the CPS ≥10 population (9.3 months vs 6.7 months; HR 0.69; 95% CI 0.52-0.93), with grade 3-5 treatment-related adverse events in 18% versus 41% ^[45]B2b. For patients with MSI-H or dMMR tumors, pembrolizumab is approved across solid tumor types, with an ORR of 53% reported in a phase 2 study ^[45]B2b. Nivolumab has also shown activity in pretreated esophageal cancer, with an ORR of 17% and median OS of 10.8 months in a phase 2 study ^[45]B2b.

Predictive Biomarkers

PD-L1 combined positive score (CPS) is the most important predictive biomarker for PD-1 inhibitor efficacy in esophageal cancer ^[47]D5. The benefit of immunotherapy is most pronounced in patients with CPS ≥10, though clinically meaningful improvements are also seen in lower-expression groups ^[4]A1b. Standardized testing using validated assays (e.g., PD-L1 IHC 22C3 pharmDx) is essential for patient selection ^[47]D5. Microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) identifies a smaller subset (~1-2% of esophageal cancers) with high response rates to PD-1 inhibitors ^[45]B2b. Circulating tumor DNA (ctDNA) is an emerging biomarker: high baseline levels and early increases identify patients unlikely to benefit from treatment, though prospective validation is needed ^[12]B2b.

Targeted Therapy

Unlike in gastric and gastroesophageal junction adenocarcinoma, where trastuzumab is standard for HER2-positive disease, no targeted agent has demonstrated a survival benefit when added to chemotherapy in the first-line treatment of esophageal cancer. Anti-VEGF agents (e.g., bevacizumab ) and anti-EGFR inhibitors have not improved outcomes in phase 3 trials ^[49]D5. The combination of trifluridine-tipiracil plus bevacizumab has shown activity in refractory gastroesophageal adenocarcinoma, but its role in pure esophageal cancer remains undefined ^[12]B2b.

Emerging Agents and Future Directions

Serplulimab has been approved in China for first-line PD-L1-positive ESCC, with a favorable benefit-risk profile compared to other PD-1 inhibitors in indirect analyses ^[44]A1a. Body composition may influence ICI outcomes: a high waist circumference was associated with better PFS in patients receiving nivolumab or pembrolizumab-based therapy (multivariable HR 0.56 per 5-cm increase; 95% CI 0.33-0.94) ^[50]D5. Ongoing studies are evaluating PD-1 inhibitors in combination with CTLA-4 blockade (nivolumab plus ipilimumab ), novel immunomodulatory agents, and in perioperative settings ^[45]B2b. Adoptive T cell therapy and cancer vaccines remain investigational ^[48]D5.

Pearl: For first-line treatment of advanced esophageal cancer, pembrolizumab plus chemotherapy provides a 5-year OS of 24% in Japanese patients and 10.6% globally; PD-L1 CPS ≥10 identifies the subgroup with greatest benefit, but the survival advantage extends across histologies and PD-L1 levels ^[4]A1b.

Having reviewed the efficacy of targeted and immune therapies, the clinician must also anticipate and manage their associated toxicities. Systemic therapy for esophageal cancer , whether chemotherapy, immunotherapy, or chemoradiation, carries a predictable burden of adverse events that require active surveillance and prompt intervention. The spectrum ranges from common chemotherapy-related toxicities (neutropenia, neuropathy, thrombosis) to immune-related adverse events (irAEs) unique to checkpoint inhibitors, and radiation-induced organ damage when radiotherapy is combined.

Immune-Related Adverse Events

Immune checkpoint inhibitors (ICIs) activate T-cell responses that can attack normal tissues. In real-world cohorts, grade 3 or higher irAEs occurred in 14% of patients receiving second-line nivolumab monotherapy and in 13% of those receiving ICI combination therapy (ICI + chemotherapy or ICI + ICI) ^{[10]B2b[39]C4}. One treatment-related death from cholangitis was reported in the combination therapy group ^[39]C4. Importantly, the occurrence of irAEs is independently associated with improved progression-free survival (PFS) and overall survival (OS). In a retrospective study of 100 patients, those who developed any irAE had significantly longer PFS and OS compared with those who did not (P < 0.001 and P = 0.020, respectively), and irAE occurrence was an independent predictor of longer PFS on multivariate analysis (P = 0.003) ^[18]C4. This paradoxical relationship suggests that irAEs may serve as a surrogate marker for immune activation and treatment benefit.

Management of irAEs follows established guidelines: low-grade events (grade 1-2) often resolve with symptomatic treatment and temporary ICI hold; grade 3 or higher events typically require systemic corticosteroids (e.g., prednisone 1-2 mg/kg/day) and permanent discontinuation of the offending agent. Specific organ involvement (colitis, pneumonitis, hepatitis, dermatitis) dictates additional workup and tailored therapy.

Chemotherapy-Related Toxicities

Although the provided evidence does not report specific rates for chemotherapy-related toxicities, standard regimens (platinum/fluoropyrimidine, taxanes) are associated with myelosuppression, peripheral neuropathy , nausea, and venous thromboembolism. Supportive care includes growth factor support for neutropenia, dose reductions or delays for neuropathy, antiemetic prophylaxis, and anticoagulation for thrombosis. Close monitoring of blood counts and renal function is essential.

Radiation-Related Toxicities

When systemic therapy is combined with definitive radiotherapy, radiation-induced toxicities are common. In a multi-center study of T1-2N0M0 esophageal squamous cell carcinoma treated with definitive radiotherapy (median dose 60 Gy), the incidence of radiation pneumonitis was 14.80% (29/196) and radiation esophagitis was 65.82% (129/196) ^[52]B3b. The vast majority of these events were grade 1-2; no grade 4 toxicity was observed ^[52]B3b. Management of radiation esophagitis includes oral analgesics, topical anesthetics, dietary modifications (soft, bland foods), and proton pump inhibitors for reflux. Radiation pneumonitis is treated with corticosteroids and supportive care; severe cases may require oxygen and hospitalization.

Prognostic Factors and Supportive Care

Beyond toxicity management, baseline patient factors influence tolerance and outcomes. Myosteatosis (low skeletal muscle radiodensity) without systemic inflammation (neutrophil-to-lymphocyte ratio ≤ 2.8) was independently associated with favorable PFS and OS in patients receiving definitive chemoradiotherapy (HR for progression 0.47, 95% CI 0.26-0.85; HR for death 0.39, 95% CI 0.21-0.72) ^[51]B3b. Conversely, elevated C-reactive protein and poor performance status predict worse survival in patients receiving ICI therapy ^{[10]B2b[39]C4}. These factors should inform pre-treatment risk stratification and supportive care planning.

Pearl: The occurrence of immune-related adverse events, while requiring active management, is paradoxically associated with improved progression-free survival in patients receiving ICI therapy for esophageal cancer; this association should not deter clinicians from treating toxicities but may inform prognostic discussions ^[18]C4.

The toxicity profile of systemic therapy is amplified in patients with baseline vulnerabilities, making performance status, age, organ function, and nutritional reserve critical determinants of treatment selection and outcomes.

Performance Status and Frailty

Performance status (PS) is one of the strongest prognostic factors across all treatment settings. In second-line nivolumab monotherapy, PS was a significant predictor of overall survival ^[10]B2b. Among patients receiving immune-checkpoint inhibitor combination therapy, good PS and low C-reactive protein levels identified those most likely to benefit ^[39]C4. Poor PS ( ECOG 2-4) independently increased mortality (HR 1.38) and predicted poor response to concurrent chemoradiotherapy ^[60]D5. In the trimodality versus bimodality decision, worse PS was associated with receipt of bimodality therapy (definitive chemoradiation without surgery), which carried significantly lower survival (3-year OS 18% vs 62%) ^[56]B3b. Sarcopenia, measured by skeletal muscle index (SMI) at L3, increases postoperative complications:

• Overall morbidity: RR 1.16 (95% CI 1.01-1.33)
• Respiratory complications: RR 1.64 (95% CI 1.21-2.22)
• Anastomotic leaks: RR 1.39 (95% CI 1.10-1.76) Preoperative nutritional optimization and closer postoperative vigilance are warranted in sarcopenic patients ^[53]B2a.

Elderly Patients

Older age alone should not preclude aggressive therapy, but age-adjusted comorbidity burden often drives treatment selection. In a real-world cohort, patients receiving bimodality therapy had higher age-adjusted comorbidity indices and were more likely to hold chemotherapy cycles ^[56]B3b. For patients with cervical lymph node metastasis, those receiving radiotherapy alone were the oldest (mean age 74 years) and had the poorest survival (median OS 7 months) ^[27]B2b. Definitive chemoradiotherapy remains an option for fit elderly patients, though careful dose selection and supportive care are essential.

Renal Impairment

Cisplatin -based regimens, common in esophageal cancer , require adequate renal function. In a randomized trial of Xiaoaiping plus S-1/cisplatin, renal impairment was reported as an adverse event in both arms ^[17]A1b. No specific dose modifications are provided in the available evidence; clinicians should follow standard cisplatin renal dosing guidelines and consider carboplatin substitution when creatinine clearance is <60 mL/min.

HIV/AIDS and Immunocompromised Patients

No dedicated studies in the provided evidence address systemic therapy for esophageal cancer in patients with HIV/AIDS or other immunocompromised states. Immune checkpoint inhibitors carry a theoretical risk of immune-related adverse events in the setting of preexisting immune dysregulation. Multidisciplinary management with infectious disease consultation is recommended.

Cervical Lymph Node Metastasis

Cervical lymph node metastasis (CLNM) represents a conceptual border zone between locoregional and distant disease. In a Dutch nationwide cohort, management was highly heterogeneous. Neoadjuvant therapy followed by surgery was associated with longer survival compared with definitive chemoradiotherapy (HR 0.56, 95% CI 0.34-0.91; median OS 24 vs 18 months; 3-year OS 38% vs 21%) ^[27]B2b. Higher cN stage and poorer PS were independently associated with worse survival. Surgery may be considered in carefully selected patients with CLNM as part of multimodality treatment.

Pearl: Performance status (ECOG ≥2) is the single most powerful predictor of treatment failure and mortality across all systemic therapy settings; objective assessment of sarcopenia via SMI can further refine perioperative risk stratification.

Part of the Esophageal Cancer family. Cross-cutting management is split across dedicated child pages:

• Esophageal Cancer , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
• Esophageal Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
• Esophageal Cancer Radiation Management , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
• Esophageal Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
• Esophageal Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
• Esophageal Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease

Pearl: Use these links to hop between management modalities; the parent Esophageal Cancer page carries diagnosis + staging that informs every decision here.